Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 17/20 | 0.67 |
| ▸ | EGFR | P00533 | 15/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 10/20 | 0.63 |
| ▸ | JAK3 | P52333 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | RGS12 | O14924 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249277 | 0.91 | ERBB2 (0.61) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL2248227 | 0.86 | ERBB2 (0.60) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6883721 | 0.86 | ERBB2 (0.76) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6773200 | 0.85 | ERBB2 (0.69) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL3323462 | 0.83 | ERBB2 (0.74) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL31061501 | 0.82 | ERBB2 (0.76) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL8561085 | 0.82 | ERBB2 (0.76) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6763973 | 0.82 | ERBB2 (0.73) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL8363568 | 0.81 | ERBB2 (0.69) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6891343 | 0.81 | ERBB2 (0.62) | ERBB2EGFRERBB4JAK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ERBB2 1693/4885EGFR 1400/4885ERBB4 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.